BioPharma Lung Cancer Drug Fails to Meet Main Goal in Study

By Jennifer Booton Features FOXBusiness

Array BioPharma (ARRY) said its lung cancer drug failed to meet the primary goal in a mid-stage study of demonstrating statistical significance of overall survival.

Continue Reading Below

In the study, which was conducted by AstraZeneca (AZN), the drug, called selumetinib, was tested in 87 patients with non-small-cell lung cancer.

While the treatment demonstrated a numerically greater increase in survival, the statistical improvement fell short when compared with chemotherapy drug docetaxel.

The study's second most important goals, however, including progression-free survival, objective response rate, and alive and progression-free at six months, all demonstrated statistical significance over the placebo.

Non-small-cell lung cancer is one of the leading causes of cancer-related mortality in the U.S., and some 186,000 new cases have been estimated for 2011.

The drug was licensed by AstraZeneca, which is also conducting a mid-stage trial with selumetinib as a treatment for melanoma.